Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct:6:1666-1673.
doi: 10.1200/GO.20.00497.

Recommendations from the ASCO Academic Global Oncology Task Force

Affiliations

Recommendations from the ASCO Academic Global Oncology Task Force

Julie R Gralow et al. JCO Glob Oncol. 2020 Oct.

Abstract

In recognition of the rising incidence and mortality of cancer in low- and middle-resource settings, as well as the increasingly international profile of its membership, ASCO has prioritized efforts to enhance its engagement at a global level. Among the recommendations included in the 2016 Global Oncology Leadership Task Force report to the ASCO Board of Directors was that ASCO should promote the recognition of global oncology as an academic field. The report suggested that ASCO could serve a role in transitioning global oncology from an informal field of largely voluntary activities to a more formal discipline with strong research and well-defined training components. As a result of this recommendation, in 2017, ASCO formed the Academic Global Oncology Task Force (AGOTF) to guide ASCO's contributions toward formalizing the field of global oncology. The AGOTF was asked to collect and analyze key issues and barriers toward the recognition of global oncology as an academic discipline, with an emphasis on training, research, and career pathways, and produce a set of recommendations for ASCO action. The outcome of the AGOTF was the development of recommendations designed to advance the status of global oncology as an academic discipline.

PubMed Disclaimer

Conflict of interest statement

Julie R. Gralow

Consulting or Advisory Role: Novartis, Genentech, Pfizer, Merck, Puma Biotechnology, Sandoz, AstraZeneca, Immunomedics, Genomic Health

Fredrick Chite Asirwa

Research Funding: Celgene (Inst), Takeda Pharmaceuticals, Eli Lilly, Bristol Myers Squibb, Takeda Pharmaceuticals (Inst)

Ami Siddharth Bhatt

Employment: January.ai (I), Varian Medical Systems (I)

Honoraria: Illumina

Consulting or Advisory Role: Janssen Research & Development, ArcBio, January.ai, January.ai (I), Kaleido Biosciences, Caribou Biosciences, Guardant Health, BiomX

Research Funding: Agilent

Travel, Accommodations, Expenses: Illumina, Oxford Nanopore Technologies

Maria T. Bourlon

Honoraria: Tecnofarma

Consulting or Advisory Role: Bristol Myers Squibb, Asofarma, Eisai, MSD Oncology, Janssen Oncology, Novartis, Bayer AG

Speakers’ Bureau: Asofarma, MSD Oncology, Bristol Myers Squibb, Bayer AG, Eisai, Janssen Oncology, Ipsen

Expert Testimony: Asofarma

Travel, Accommodations, Expenses: Asofarma, Janssen Cilag, MSD Oncology, Bristol Myers Squibb, Pfizer

Alexandru E. Eniu

Research Funding: Roche, Celltrion, Pfizer

Patrick J. Loehrer

Research Funding: Novartis (Inst), Lilly Foundation (Inst), Taiho Pharmaceutical (Inst)

Patents, Royalties, Other Intellectual Property: US PPA/61/499,988 Gene Expression Analysis of Thymic Neoplasms Inventors: Sunil Badve, Yesim Gokmen-Polar, Patrick Loehrer (Inst)

Gilberto Lopes

Honoraria: Boehringer Ingelheim

Consulting or Advisory Role: Pfizer, AstraZeneca

Research Funding: Merck Sharp & Dohme (Inst), EMD Serono (Inst), AstraZeneca (Inst), AstraZeneca, Blueprint Medicines (Inst), Tesaro (Inst), Bavarian Nordic (Inst), Novartis (Inst), G1 Therapeutics (Inst), Adaptimmune (Inst), Bristol Myers Squibb (Inst), GlaxoSmithKline (Inst), AbbVie (Inst), Rgenix (Inst), Pfizer (Inst), Roche (Inst), Genentech (Inst), Eli Lilly (Inst), Janssen Pharmaceuticals (Inst)

Travel, Accommodations, Expenses: Boehringer Ingelheim, Pfizer, E.R. Squibb Sons, Janssen Pharmaceuticals

Lawrence N. Shulman

Research Funding: Celgene

Michal Tibbits

Consulting or Advisory Role: Regenex Bio (I), CTI BioPharma (I)

No other potential conflicts of interest were reported.

References

    1. Bray F, Ferlay J, Soerjomataram I, et al: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394-424, 2018 [Erratum: CA Cancer J Clin 70:313, 2020] - PubMed
    1. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the Human Development Index (2008-2030): A population-based study. Lancet Oncol. 2012;13:790–801. - PubMed
    1. Knaul FM, Arreola-Ornelas H, Rodriguez NM, et al: Avoidable mortality: The core of the global cancer divide. J Glob Oncol 10.1200/JGO.17.00190. - DOI - PMC - PubMed
    1. United Nations Department of Public Health Information: 2011 High Level Meeting on Prevention and Control of Non-Communicable Diseases. http://www.un.org/en/ga/ncdmeeting2011.
    1. WHO: Cancer prevention and control in the context of an integrated approach, 2016. https://apps.who.int/gb/ebwha/pdf_files/EB140/B140_31-en.pdf.

Publication types